Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?

Growth factors for diabetic foot ulcers: mixed treatment comparison analysis of randomized clinical trials

“…A total of 837 articles were obtained of which 26 were found to be eligible to be included for final analysis (Figure ). There were a total of 2088 participants with 1018 events from all these eligible studies.…”

Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer Healing

“…26,27,29,36 Two multi-center, prospective clinical trials that included patients (20 and 113, respectively) with large diabetic neuropathic plantar ulcers found that treatment using becaplermin gel in conjunction with standard care accelerated the time to complete wound closure by 41.8% (50 versus 86 days) and 40.6% (57 versus 96 days), respectively. 37,38 The improved healing rates, shorter healing times, and reduction in WSA associated with becaplermin gel have important implications for the direct medical costs of treating DFUs. Costeffectiveness studies on the direct cost of care for DFU therapy included healing as the only primary outcome and did not include other potential surrogate endpoints, such as cost per cm 2 of WSA reduction.…”

Safety and efficacy of Becaplermin gel in the treatment of diabetic foot ulcers

“…12 In 2009, Bhansali et al published a study comparing standard wound care and use of Becaplermin gel in 17 patients offloaded with a total contact cast for 20 weeks or until the ulcer healed. 13 All ulcers healed in both groups; however, the group treated with Becaplermin gel healed faster. 13 The group treated with Becaplermin healed in an average of 50.10 days compared with the standard wound care group for whom healing occurred in an average of 86.10 days.…”

“…13 All ulcers healed in both groups; however, the group treated with Becaplermin gel healed faster. 13 The group treated with Becaplermin healed in an average of 50.10 days compared with the standard wound care group for whom healing occurred in an average of 86.10 days. 13 Becaplermin gel's efficacy has been demonstrated in numerous studies; however, less studied is its comparison with or its use in combination with other biological agents.…”

“…13 The group treated with Becaplermin healed in an average of 50.10 days compared with the standard wound care group for whom healing occurred in an average of 86.10 days. 13 Becaplermin gel's efficacy has been demonstrated in numerous studies; however, less studied is its comparison with or its use in combination with other biological agents. Kirsner et al published a retrospective cohort study, in 2010, comprising 2,517 patients with diabetic foot ulcers that were treated with an advanced biologic therapy, including Becaplermin gel, bilayered living cell therapy (Apligraf ® ; Organogenesis Inc., Canton, MA, USA), platelet releasate (Procuren ® ; Cytomedix, Gaithersburg, MD, USA), or Becaplermin gel, or Procuren followed by Apligraf.…”